Showing 1251-1260 of 1635 results for "".
- Bausch + Lomb Receives CE Mark Approval for Preloaded LuxLife Full Range of Vision IOLshttps://modernod.com/news/bausch-lomb-receives-ce-mark-approval-for-preloaded-luxlife-full-range-of-vision-iols/2482789/Bausch + Lomb has received CE Mark approval for the LuxLife full range of vision IOLs. According to B+L, the preloaded IOL provides patients with natural, continuous vision, from distance to near. In a multicenter, comparative clinical study evaluating the LuxLife IOL versus t
- Allotex Accelerates into Commercial Phase and Appoints Michael Mrochen as New CEOhttps://modernod.com/news/allotex-accelerates-into-commercial-phase-and-appoints-michael-mrochen-as-new-ceo/2482755/Allotex, which has developed the first natural, human collagen-based eye implant designed to help people over 40 restore their near vision, announced progress in its commercial rollout across global markets. Following market clearance in Europe, Canada, South Africa, Türkiye, and A
- Prevent Blindness Announces Matt MacDonald as Chair-Elect of Board of Directorshttps://modernod.com/news/prevent-blindness-announces-matt-macdonald-as-chair-elect-of-board-of-directors/2482708/Prevent Blindness, a nonprofit organization dedicated to eye health and safety awareness, named Matt MacDonald as Chair-elect of its Board of Directors. The vote was held last week during the Spring 2025 Board Meeting. He will succeed current Board of Directors Chair Jim McGrann, CEO of Adva
- Experimental Stem Cell Treatment Shows Success in Restoring Corneashttps://modernod.com/news/experimental-stem-cell-treatment-shows-success-in-restoring-corneas/2482700/A clinical trial testing an stem cell treatment for blinding cornea injuries has shown promising results. The expanded phase 1/2 trial, published in Nature Communications[1] found the treatment to be feasible and safe for 14 pa
- Study Finds Most Glaucoma Patients Unaware of Preservative-Free Treatment Optionshttps://modernod.com/news/60-of-glaucoma-patients-unaware-of-preservative-free-treatment-options-study-from-preservative-freedom-coalition/2482698/The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glaucoma patients to identify opportunities for improved communication with their eye care providers. This comes as Monday kicked o
- Formycon Receives Approval in the UK for Eylea Biosimilarhttps://modernod.com/news/formycon-receives-approval-in-the-uk-for-eylea-biosimilar/2482680/Formycon and its licensing partner Klinge Biopharma jointly announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved FYB203 (aflibercept), a biosimilar to Eylea (Regeneron), under the brand name Ahzantine. The approval covers the treatment
- Call for Nominations: Prevent Blindness Seeks to Honor Leaders in Vision Healthhttps://modernod.com/news/call-for-nominations-prevent-blindness-seeks-to-honor-leaders-in-vision-health/2482661/Prevent Blindness, one of the nation’s largest eye health and safety nonprofit organizations, issued their call for nominations for the “
- AAO Responds to Proposed Cuts to NIH Research Paymentshttps://modernod.com/news/aao-responds-to-proposed-cuts-to-nih-research-payments/2482660/The National Institutes of Health (NIH) announced Friday that it is cutting grants that support research and academic institutions by limiting the amount of indirect funding for research projects to just 15%. Currently, the average indirect costs rate for organizations receiving NIH grants is bet
- Visible Genomics Wins 2025 AMD Genetic Testing Company of the Year Awardhttps://modernod.com/news/visible-genomics-wins-2025-amd-genetic-testing-company-of-the-year-award/2482619/Visible Genomics, a provider of genetic testing solutions for severe ocular diseases, was named 'Life Sciences Review AMD Genetic Testing Company of the Year 2025.' This award recognizes the company’s innovative contributions to proactive care for advanced age-related macular degene
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety